<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 30, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370236</url>
  </required_header>
  <id_info>
    <org_study_id>XPro1595-COVID-19</org_study_id>
    <nct_id>NCT04370236</nct_id>
  </id_info>
  <brief_title>XPro1595 for the Treatment of Pulmonary Complications From COVID-19</brief_title>
  <official_title>Phase 2 Randomised Trial Using XPro1595 to Treat Participants With Pulmonary Complications From Coronavirus Disease (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inmune Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inmune Bio, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether XPro1595 can prevent the progression of
      respiratory complications in COVID19 patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical trial is a Phase 2, open-label, randomized clinical trial of XPro1595 in
      participants with pulmonary complications due to COVID-19 infection.

      Patients with COVID-19 infection and a room air oxygen saturation (SaO2) &gt;93% are eligible to
      participate in a 28-day study to determine whether XPro1595 can prevent the progression of
      pulmonary complications.

      Eligible participants will be randomized (1:1) to receive either XPro1595 at 1mg/kg by
      subcutaneous injection (SC) + standard of care (SOC) or SOC alone. Participants randomized to
      XPro1595 + SOC will receive their first dose of XPro1595 after randomization and a second
      dose 7 days later. A final safety visit will occur on Day 28.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Standard of Care vs. XPro1595 + Standard of Care</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with treatment failure</measure>
    <time_frame>28 days</time_frame>
    <description>Treatment failure is defined by progression to one of the following:
Transfer to ICU
Need for mechanical
New onset myocardial infarction or congestive heart failure
Requirement for renal replacement therapy
New onset of neurologic symptoms
New onset of thrombotic or embolic event
Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with an increase in the World Health Organization (WHO) Ordinal Scale of Clinical Improvement</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with all-cause mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of index-hospital stay</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU level of care</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Days with Fever</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Readmission before day 28 for any reason due to COVID-19</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive standard medical care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XPro1595 + Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive XPro1595 plus standard medical care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XPro1595</intervention_name>
    <description>Patients will receive a weekly injection of 1mg/kg XPro1595 for 2 weeks</description>
    <arm_group_label>XPro1595 + Standard of Care</arm_group_label>
    <other_name>DN-TNF, INB03, XENP345</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged &gt; 50 years old

          -  Have a positive COVID-19 test in last 28 days

          -  Have a room air SaO2 &lt;93%

          -  Have abnormal chest X-ray, MRI or CT scan consistent with pulmonary complications from
             COVID-19

          -  Provide written informed consent prior to any study-related procedures being
             performed.

        Exclusion Criteria:

          -  Require immediate intubation due to advanced respiratory failure

          -  Require immediate admission to an Intensive Care Unit for any reason

          -  On current therapy with approved Tumor Necrosis Factor (TNF) inhibitor (eg:
             thalidomide)

          -  Being treated with corticosteroids dose of &gt;10mg per day

          -  Taking any medication known to be Chemokine Receptor 5 antagonist (eg: leronlimab,
             aplaviroc, vicriviroc or maraviroc)

          -  Taking any medication known to inhibit the cytokine pathway (eg: anakinra,
             tocilizumab, siltuximab, etc)

          -  Known to be pregnant

          -  Significant hepatic disease (ALT/AST&gt; 4 times the ULN)

          -  On current therapy for cancer

          -  Known hypersensitivity to investigational product or its excipients

          -  Participating in an investigational drug or device trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher Barnum, PhD</last_name>
    <phone>+1 (858) 964-3720</phone>
    <email>trials@inmunebio.com</email>
  </overall_contact>
  <link>
    <url>http://www.inmunebio.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TNF</keyword>
  <keyword>XPro1595</keyword>
  <keyword>DN-TNF</keyword>
  <keyword>cytokine storm</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

